News coverage about Mirati Therapeutics (NASDAQ:MRTX) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.9526538772948 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
A number of brokerages recently commented on MRTX. Barclays began coverage on shares of Mirati Therapeutics in a research note on Monday, March 12th. They issued an “overweight” rating and a $44.00 price objective on the stock. HC Wainwright increased their price objective on shares of Mirati Therapeutics to $40.00 and gave the company a “buy” rating in a research note on Monday, March 12th. Zacks Investment Research cut shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th. SunTrust Banks increased their price objective on shares of Mirati Therapeutics to $40.00 and gave the company a “buy” rating in a research note on Friday, March 9th. Finally, BidaskClub raised shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company. Mirati Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.44.
Shares of NASDAQ MRTX opened at $30.95 on Tuesday. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $37.62. The stock has a market capitalization of $902.93, a P/E ratio of -11.13 and a beta of 2.14.
Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.06). equities analysts anticipate that Mirati Therapeutics will post -2.53 earnings per share for the current year.
In other Mirati Therapeutics news, CFO Jamie A. Donadio sold 12,100 shares of the firm’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $35.00, for a total transaction of $423,500.00. Following the sale, the chief financial officer now directly owns 12,100 shares of the company’s stock, valued at approximately $423,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jamie Christensen sold 23,000 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $30.00, for a total transaction of $690,000.00. Following the sale, the senior vice president now directly owns 10,877 shares in the company, valued at $326,310. The disclosure for this sale can be found here. Insiders have sold a total of 99,475 shares of company stock worth $2,847,244 over the last ninety days. 5.10% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/17/mirati-therapeutics-mrtx-earns-coverage-optimism-rating-of-0-08.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.